AMARIN CORP PLC -ADR (AMRN) Fundamental Analysis & Valuation

NASDAQ:AMRN • US0231114044

Current stock price

14.46 USD
+0.51 (+3.66%)
Last:

This AMRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. AMRN Profitability Analysis

1.1 Basic Checks

  • AMRN had negative earnings in the past year.
  • In the past year AMRN had a positive cash flow from operations.
  • In the past 5 years AMRN reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: AMRN reported negative operating cash flow in multiple years.
AMRN Yearly Net Income VS EBIT VS OCF VS FCFAMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • AMRN has a better Return On Assets (-5.78%) than 84.53% of its industry peers.
  • AMRN has a Return On Equity of -8.45%. This is amongst the best in the industry. AMRN outperforms 87.81% of its industry peers.
Industry RankSector Rank
ROA -5.78%
ROE -8.45%
ROIC N/A
ROA(3y)-8.29%
ROA(5y)-7.22%
ROE(3y)-12.02%
ROE(5y)-10.54%
ROIC(3y)N/A
ROIC(5y)N/A
AMRN Yearly ROA, ROE, ROICAMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400 600 800

1.3 Margins

  • AMRN has a better Gross Margin (56.57%) than 76.21% of its industry peers.
  • AMRN's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for AMRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.11%
GM growth 5Y-6.36%
AMRN Yearly Profit, Operating, Gross MarginsAMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. AMRN Health Analysis

2.1 Basic Checks

  • AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AMRN has been increased compared to 1 year ago.
  • Compared to 5 years ago, AMRN has more shares outstanding
  • AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMRN Yearly Shares OutstandingAMRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200K 400K 600K 800K 1M
AMRN Yearly Total Debt VS Total AssetsAMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of -1.65, we must say that AMRN is in the distress zone and has some risk of bankruptcy.
  • AMRN has a Altman-Z score of -1.65. This is comparable to the rest of the industry: AMRN outperforms 51.45% of its industry peers.
  • There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -1.65
ROIC/WACCN/A
WACC7.67%
AMRN Yearly LT Debt VS Equity VS FCFAMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.34 indicates that AMRN has no problem at all paying its short term obligations.
  • AMRN has a Current ratio (3.34) which is in line with its industry peers.
  • AMRN has a Quick Ratio of 2.33. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of AMRN (2.33) is worse than 69.83% of its industry peers.
Industry RankSector Rank
Current Ratio 3.34
Quick Ratio 2.33
AMRN Yearly Current Assets VS Current LiabilitesAMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AMRN Growth Analysis

3.1 Past

  • AMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.55%, which is quite impressive.
  • AMRN shows a decrease in Revenue. In the last year, the revenue decreased by -6.55%.
  • Measured over the past years, AMRN shows a very negative growth in Revenue. The Revenue has been decreasing by -19.04% on average per year.
EPS 1Y (TTM)99.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.67%
Revenue 1Y (TTM)-6.55%
Revenue growth 3Y-16.67%
Revenue growth 5Y-19.04%
Sales Q2Q%-21%

3.2 Future

  • The Earnings Per Share is expected to grow by 142.35% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 27.58% on average over the next years. This is a very strong growth
EPS Next Y-104%
EPS Next 2Y-74.93%
EPS Next 3Y385.16%
EPS Next 5Y142.35%
Revenue Next Year-18.92%
Revenue Next 2Y-9.39%
Revenue Next 3Y-6.87%
Revenue Next 5Y27.58%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AMRN Yearly Revenue VS EstimatesAMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AMRN Yearly EPS VS EstimatesAMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

2

4. AMRN Valuation Analysis

4.1 Price/Earnings Ratio

  • AMRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AMRN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMRN Price Earnings VS Forward Price EarningsAMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, AMRN is valued cheaper than 92.46% of the companies in the same industry.
Industry RankSector Rank
P/FCF 44.69
EV/EBITDA N/A
AMRN Per share dataAMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • AMRN's earnings are expected to grow with 385.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-74.93%
EPS Next 3Y385.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMRN Dividend Analysis

5.1 Amount

  • No dividends for AMRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMRN Fundamentals: All Metrics, Ratios and Statistics

AMARIN CORP PLC -ADR

NASDAQ:AMRN (3/31/2026, 8:19:25 PM)

14.46

+0.51 (+3.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners22.41%
Inst Owner Change-18.83%
Ins Owners0.86%
Ins Owner Change0.22%
Market Cap300.66M
Revenue(TTM)213.65M
Net Income(TTM)-38.80M
Analysts42.86
Price Target12.24 (-15.35%)
Short Float %43.46%
Short Ratio5.53
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.16%
Min Revenue beat(2)-4.67%
Max Revenue beat(2)12.99%
Revenue beat(4)2
Avg Revenue beat(4)5.53%
Min Revenue beat(4)-18.83%
Max Revenue beat(4)32.65%
Revenue beat(8)4
Avg Revenue beat(8)14.03%
Revenue beat(12)8
Avg Revenue beat(12)12.22%
Revenue beat(16)10
Avg Revenue beat(16)7.99%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-100%
EPS NY rev (3m)-110.53%
Revenue NQ rev (1m)2.35%
Revenue NQ rev (3m)2.35%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-13.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.41
P/FCF 44.69
P/OCF 44.69
P/B 0.65
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)0.32
FCFY2.24%
OCF(TTM)0.32
OCFY2.24%
SpS10.28
BVpS22.09
TBVpS21.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.78%
ROE -8.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.57%
FCFM 3.15%
ROA(3y)-8.29%
ROA(5y)-7.22%
ROE(3y)-12.02%
ROE(5y)-10.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.11%
GM growth 5Y-6.36%
F-Score6
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.34
Quick Ratio 2.33
Altman-Z -1.65
F-Score6
WACC7.67%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.67%
EPS Next Y-104%
EPS Next 2Y-74.93%
EPS Next 3Y385.16%
EPS Next 5Y142.35%
Revenue 1Y (TTM)-6.55%
Revenue growth 3Y-16.67%
Revenue growth 5Y-19.04%
Sales Q2Q%-21%
Revenue Next Year-18.92%
Revenue Next 2Y-9.39%
Revenue Next 3Y-6.87%
Revenue Next 5Y27.58%
EBIT growth 1Y75.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y121.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y121.69%
OCF growth 3YN/A
OCF growth 5YN/A

AMARIN CORP PLC -ADR / AMRN Fundamental Analysis FAQ

What is the fundamental rating for AMRN stock?

ChartMill assigns a fundamental rating of 4 / 10 to AMRN.


What is the valuation status for AMRN stock?

ChartMill assigns a valuation rating of 2 / 10 to AMARIN CORP PLC -ADR (AMRN). This can be considered as Overvalued.


What is the profitability of AMRN stock?

AMARIN CORP PLC -ADR (AMRN) has a profitability rating of 3 / 10.